Becton Dickinson to acquire Bard in $24B deal

Becton Dickinson (NYSE:BDX) has inked an agreement with C. R. Bard (NYSE:BCR) to acquire the medtech company for $317.00 per Bard common share in cash and stock, valuing the deal at $24 billion. In announcing the deal yesterday, Franklin Lakes, N.J.-based BD said it plans to create a new segment within the company, BD Interventional, to

This test can detect tiny ovarian tumors sooner than current tests

Massachusetts Institute of Technology engineers have developed a way to detect ovarian tumors that are smaller than 2 mm in diameter, allowing for detection 5 months earlier than existing tests. A synthetic biomarker, which is a nanoparticle that works with tumor proteins to release fragments into the urine for detection, helps the MIT-developed test create

Proxy Biomedical Group announces new corporate brand Aran Biomedical

Proxy Biomedical, a provider of outsourced design, development and manufacturing services for implantable medical devices, announced the formation of a new group company and brand, Aran Biomedical. According to the company, the new corporate identity is part of an overall rebranding and restructuring strategy to position the company in line with the broader range of capabilities now

AVX adds medical device development facility to headquarters

AVX Corp., a maker and supplier of passive components and interconnect solutions, recently announced that it has added a new medical device development facility to its corporate headquarters, located in Fountain Inn, S.C. The new facility, announced April 18, has more than 2,500 square ft of cleanrooms and support space for device fabrication, biological analysis

Columbian regulators reduce medical device and IVD review timeframes

By Stewart Eisenhart, Emergo Group Medical device and in vitro diagnostic (IVD) market regulators in Colombia have pushed through changes to registration and modification processes with immediate effect. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not necessarily reflect those

Beaver-Visitec International to acquire Malosa Medical

Beaver-Visitec International – a developer, manufacturer, and marketer of specialized surgical devices for the ophthalmic marketplace– announced today that it has acquired Malosa Medical. Malosa Medical is a manufacturer and supplier of single-use surgical instruments, primarily for use in the field of ophthalmology. Additional terms of the transaction were not disclosed. “Fueled by an aging

MicroPort Orthopedics launches new tibial system

MicroPort Orthopedics – a medical device company that develops and manufactures joint replacement implants designed to help patients achieve full function faster – announced the launch of the Evolution revision tibial system and Evolution BioFoam tibia. “MicroPort Orthopedics continues to grow its product portfolio with a steady cadence of product launches,” said Aurelio Sahagun, president of MicroPort

Piezo Kinetics buys Channel Technologies Group’s ceramics division

Piezo Kinetics, a manufacturer of specialty piezoelectric ceramic elements and assemblies, has acquired Channel Technologies Group’s Ceramics Division assets, including all powder formulations and inventories of finished products. The Santa Barbara, Calif.–based ceramics subsidiary manufactures piezoelectric ceramics for the medical, energy, defense and commercial maritime industries. Financial terms of the cash acquisition were not disclosed. Piezo

The 10 hottest medtech startups of 2017

Medtech startups face more challenges than they have in the past, but several companies are developing products that take advantage of new technology and are specifically designed to meet healthcare’s evolving needs.    The number of medtech startups has declined. Thirty years ago, the medtech field averaged 1,500 startups; it slid to about 600 by

Pages: 1 2 3 4 5 6 7 8 9 10 11

Medtech stories we missed this week: April 21, 2017

From new and renewed partnerships to FDA approvals, here are medtech stories we missed this week but thought were still worth mentioning. 1. Life Spine receives FDA clearance for cervical spacer system Life Spine announced in an April 19 press release that it has received FDA 510(k) clearance for its Plateau-C Ti Cervical Spacer System. The system uses

6 ways hydrogels are enabling medtech innovation

Hydrogels are water-based biomaterials developed specifically for human use, according to a Biomaterials journal article. They are a water-swollen polymeric material that doesn’t change its distinct 3D structure. They are formed from super-absorbent, chain-like polymers and are not soluble in water. However, their porous surface allows for nutrients and cell waste to pass through. They have

Pages: 1 2 3 4 5 6 7

23andMe is back: FDA allows marketing of genetic health risk tests

FDA this month allowed genetic testing company 23andMe to market genetic health risk tests for 10 diseases and conditions including Parkinson’s disease and late-onset Alzheimer’s disease. The de novo premarket review authorization, announced April 6, also included celiac disease, which results in the inability to digest gluten; alpha-1 antitrypsin deficiency, which raises the risk of

Malaysian combination product regulatory policy deadlines set

By Stewart Eisenhart, Emergo Group Malaysian medical device and drug market regulators have established a July 2018 implementation and enforcement deadline for combination product registrations marketed in the country. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not necessarily reflect

GOP reportedly near completion of new healthcare bill – but support is split

Republican lawmakers are closing in on a new healthcare bill that would start dismantling and replacing Obamacare, according to a report from The Hill. Freedom Caucus chair Rep. Mark Meadows (R-N.C.) and moderate Tuesday Group co-chair Rep. Tom MacArther (R-N.J.) are brokering the compromised piece, according to the report. The revised plan would reportedly allow

Report: New FDA guidance release rate falls post-Trump election

The FDA hoped to release more than 100 draft guidance documents this year, but has only released 6 documents since Trump’s inauguration, according to a Regulatory Affairs Professional Society’s Regulatory Focus report. Since January 20, nearly 3 months ago, the agency has only released 2 guidance documents and 4 final guidances, according to the report.